Leveraging our World Class Commercial Channel | Genomic Health, Inc.
Leveraging Our World Class Commercial Channel and Leading Brand to Advance Genomic Medicine
We deliver more than 400 Oncotype DX test results per day to more than 90 countries through our centralised clinical laboratory, serving health professionals and patients with our industry-leading customer service team and more than 200 sales and managed-care representatives around the world.
For more than a decade, Genomic Health has led the translation of genomic information into practice-changing tests that help patients and health professionals answer key questions about the aggressiveness of and appropriate treatment for early-stage cancer. Using our proven scientific, operational and commercial capabilities, we intend to remain at the forefront of innovation.
In the next decade, we aim to accelerate this effort by developing a pipeline of products and services for managing treatment decision-making throughout the cancer patient journey. These new offerings will include mutation panels, liquid-based monitoring tests to track tumour status and treatment effectiveness and a web-based information platform to gather and help evaluate patient test results over time.
To support our continued innovations in the field of genomic medicine, we plan to leverage our trusted brand and world-class commercial infrastructure, which includes:
A centralised clinical reference laboratory receiving samples from more than 90 countries and delivering more than 400 test results per day or more than 100,000 test results each year
An industry-leading customer service team, speaking 13 languages and handling more than 500 interactions with patients and healthcare professionals daily
A team of university-trained, board-certified surgical pathologists who examine and guide each cancer specimen through our analytical laboratory
A multi-disciplinary case review team employing digital imaging, biostatistical analysis, and clinical expertise to address medical enquiries and requests
With support from this leading global commercial channel, our Oncotype DX® tests in three major cancers – breast, colon and prostate – have helped more than 700,000 patients worldwide so far to personalise their cancer care.
Learn more about Genomic Health
Oncotype IQ Products
Turning insight into action. Learn about the power of the IQ portfolio.
Oncotype DX helps with cancer treatment decisions.
See how Genomic Health is using next generation technology to transform treatment decision making throughout the cancer patient journey